Analyst Price Targets — JANX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 8:58 am | — | UBS | $15.00 | $15.24 | TheFly | Janux Therapeutics downgraded to Neutral from Buy at UBS |
| January 16, 2026 11:55 am | Kelsey Goodwin | Piper Sandler | $30.00 | $13.72 | TheFly | Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler |
| December 17, 2025 10:58 am | — | Barclays | $29.00 | $14.65 | TheFly | Janux Therapeutics price target lowered to $29 from $48 at Barclays |
| December 2, 2025 12:40 pm | David Dai | UBS | $57.00 | $17.28 | StreetInsider | Janux Therapeutics (JANX) Reiterated at Buy by UBS After JANX007 Ph1 update |
| December 2, 2025 12:15 pm | Stephen Willey | Stifel Nicolaus | $38.00 | $33.99 | TheFly | Janux Therapeutics price target lowered to $38 from $46 at Stifel |
| December 2, 2025 11:11 am | — | H.C. Wainwright | $45.00 | $33.99 | TheFly | Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright |
| September 16, 2025 8:51 pm | — | Barclays | $47.00 | $23.41 | TheFly | Janux Therapeutics initiated with an Overweight at Barclays |
| September 10, 2025 9:12 am | — | Stifel Nicolaus | $45.00 | $24.31 | TheFly | Janux Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:25 pm | Brad Canino | Guggenheim | $72.00 | $23.04 | TheFly | Janux Therapeutics initiated with a Buy at Guggenheim |
| July 11, 2025 10:46 am | Sean McCutcheon | Raymond James | $65.00 | $25.15 | TheFly | Janux Therapeutics initiated with an Outperform at Raymond James |
Latest News for JANX
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed…
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic,…
Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JANX.
U.S. House Trading
No House trades found for JANX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.